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Objectives. In the present study, we investigated, in transplant
recipients, whether L-arginine (L-arg) potentiates the myocardial
contractile effects of receptor-mediated coronary endothelial stim-
ulation. Moreover, because inducible nitric oxide synthase (iNOS)
is frequently expressed in transplanted myocardium, we also
performed intracoronary infusion of L-arg in the absence of
receptor-mediated coronary endothelial stimulation to investigate
whether similar left ventricular (LV) contractile effects could be
induced by providing more substrate for iNOS.
Background. Nitric oxide (NO), released from coronary endo-
thelium after receptor-mediated stimulation by substance P (SP),
affects vascular smooth muscle tone and modulates LV contractile
performance. L-arg augments receptor-mediated endothelium-
dependent coronary vasodilation in transplant recipients by in-
creasing substrate availability for endothelial NO production.
Methods. Sixteen transplant recipients were studied at the time
of annual coronary angiography. In eight transplant recipients,
microtip LV pressures were recorded before and during intracoro-
nary (IC) SP (20 pmol/min) and after the addition of IC L-arg (160
mmol/min) to IC SP. In eight transplant recipients, microtip LV
pressures were recorded before and during IC L-arg (160 mmol/
min) alone, and in six of these patients, endomyocardial biopsy
samples were obtained to detect the expression of iNOS gene by
reverse transcription–polymerase chain reaction.
Results. Addition of IC L-arg to IC SP induced a fall (mean 6
SEM) in LV peak systolic pressure (216 6 4 mm Hg), which was
larger (p < 0.01) than that observed during IC SP (27 6
2 mm Hg). During IC L-arg alone, there was no change in LV peak
systolic pressure despite the presence of iNOS mRNA in five of the
six biopsy samples.
Conclusions. In transplant recipients, L-arg potentiates the
paracrine myocardial contractile effects of receptor-mediated cor-
onary endothelial stimulation, probably by providing more sub-
strate for endothelial NO production. Despite the myocardial
expression of iNOS gene, L-arg alone fails to elicit similar
contractile effects.
(J Am Coll Cardiol 1997;29:1332–8)
©1997 by the American College of Cardiology
Nitric oxide (NO), derived from NO donors or produced by
endothelial cells, has recently been demonstrated to influence
myocardial contractile performance of the human heart, as
evident from the development of lower left ventricular (LV)
systolic pressure and increased LV diastolic distensibility ob-
served during bicoronary infusion of sodium nitroprusside (1)
or substance P (SP) (2), which releases NO from coronary
endothelium. These hemodynamic changes were attributed to
a direct, probably 39,59-cyclic guanosine monophosphate (cGMP)–
mediated, myocardial action of NO. They were unrelated to
peripheral vasodilation because right atrial infusion failed to
reproduce these effects and also appeared unrelated to auto-
nomic reflexes because similar results were observed in transplant
recipients who have deficient afferent cardiac innervation (3).
In transplant recipients (4), L-arginine (L-arg) administra-
tion improves agonist-induced endothelium-dependent coro-
nary vasodilation, probably by increasing substrate availability
for coronary endothelial NO production. In the present study,
we investigated, in transplant recipients, whether the LV
myocardial contractile effects of NO, released from the coro-
nary endothelium during intracoronary (IC) infusion of SP,
could be potentiated by IC co-infusion of L-arg. Moreover,
because of the frequent myocardial expression of inducible NO
synthase (iNOS) in the human cardiac allograft (5) as a result
of long-term exposure to rejection-related cytokines, we also
infused IC L-arg without IC infusion of SP to investigate
whether similar LV myocardial contractile effects could be
induced by providing more substrate for myocardial iNOS,
which causes a sustained, large, L-arg transport–dependent
production of NO (6–8). These observations may also be
relevant to congestive cardiomyopathy because of the recent
demonstration of iNOS gene expression in patients with non-
ischemic congestive cardiomyopathy (9,10) and the recently
reported effects of intravenous (11) and oral (12,13) L-arg in
heart failure.
Methods
Patients. Sixteen patients were studied at the time of
annual cardiac catheterization and coronary angiography 1
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year (n 5 1), 2 years (n 5 3), 3 years (n 5 7), 4 years (n 5 3),
5 years (n 5 1) and 6 years (n 5 1) after orthotopic heart
transplantation (2 women, 14 men; mean age 52 years, range
26 to 65). All patients were receiving immunosuppres-
sive therapy, consisting of various combinations of cyclo-
sporine, prednisone and azathioprine. For ethical reasons,
immunosuppressive therapy and antihypertensive medications
(angiotensin-converting enzyme inhibitors [n 5 7], calcium
channel blockers [n 5 7] and beta-adrenergic blocking agents
[n 5 1]) were continued at the time of study. No patient was
taking digitalis at the time of study.
Coronary angiography, which preceded the study protocol,
revealed angiographically normal coronary arteries without
evidence of accelerated graft atherosclerosis (14). LV angiog-
raphy, which was performed after the study protocol, showed
normal LV end-diastolic volume index (mean [6SEM] 59 6
9 ml/m2) and normal LV ejection fraction (77 6 7%) in all
patients. No patient had biopsy evidence requiring adjustment
of therapy at the time of study. Informed consent was obtained
from all patients. The study protocol was approved by the local
ethical committee, and there were no complications related to
procedure or study protocol.
Study protocol. As described previously (1,2), left and right
heart catheterization was performed from the right and left
femoral arteries and the right femoral vein. LV pressure was
measured with a high fidelity tip micromanometer catheter
calibrated externally against a mercury reference and matched
against lumen pressure. To achieve homogenous delivery of SP
or L-arg, or both, to all portions of the left ventricle, a
bicoronary infusion technique was used (1,2), except in four
patients with a left dominant coronary system and three with a
right dominant coronary system in whom simultaneous stable
coronary catheter positions in both coronary ostia could not be
achieved. In the latter two groups of patients, only the left
coronary artery was infused. When a bicoronary infusion
technique was used, the dose of SP or L-arg, or both, was
divided between the two coronary arteries, in accordance with
coronary anatomy (1,2). When only left coronary artery infu-
sion was used, the entire dose of SP or L-arg, or both, was
infused in the left coronary artery. As described in our previous
study (2), the total dose of SP was progressively increased from
2.5 to 20 pmol/min, which was then kept constant throughout
the entire protocol. A total dose of L-arg of 160 mmol/min was
used throughout the entire study protocol, in accordance with
previous investigations (15,16) studying the effects of IC L-arg
on endothelium-dependent coronary vasomotion.
LV pressure, rate of change of LV pressure (LV dP/dt),
right atrial pressure and three leads of the electrocardiogram
were continuously recorded on a Gould ES 1000 multichannel
recorder (Fig. 1) before, during and for 5 minutes following the
IC infusions. Fast paper speed recordings (250 mm/s) covering
several respiratory cycles were obtained at 1-min intervals.
After baseline recordings, the first series of eight transplant
recipients received IC infusion of SP for 5 min, followed by IC
co-infusion of SP and L-arg for 8 min. The second series of
eight transplant recipients received IC infusion of L-arg for
8 min after baseline recordings, which were obtained either in
control conditions (n 5 3) or during intravenous administra-
tion of dobutamine (n 5 5). Intravenous dobutamine was
administered to enhance the eventual myocardial contractile
effects of L-arg–induced NO production (17), individually
titrated to raise rest heart rate by 20 beats/min and kept
constant (4 6 2 mg/kg body weight per min) throughout the IC
L-arg infusion and for 5 min after cessation of the IC L-arg
infusion.
Right ventricular endomyocardial biopsy samples were ob-
tained at the end of the study in all patients. In six patients,
who underwent single IC L-arg infusion, additional biopsy
samples were immediately frozen in liquid nitrogen and stored
at 280°C for subsequent detection of iNOS mRNA by reverse
transcription–polymerase chain reaction (PCR).
Reverse transcription–PCR. Quantification of iNOS mRNA
was performed by reverse transcription followed by PCR.
Reverse transcription. For first-strand cDNA synthesis, 2 mg
of total RNA was mixed with 13 reverse transcription buffer
(50 mmol/liter Tris-HCl, pH 8.3, 75 mmol/liter KCl, 3 mmol/
liter MgCl2) completed with 0.5 mmol/liter deoxynucleotide
triphosphate (Pharmacia Biosystems Ltd., Freiburg, Germany)
and 250 pmol of random hexanucleotide primers. These mix-
tures were heated to 72°C for 3 min. Then, dithiothreitol (10
mmol/liter), RNase inhibitor (2 U/100 ng of total RNA,
Amersham Buchler, Ltd., Braunschweig, Germany) and Molo-
ney murine leukemia virus reverse transcriptase (10 U/100 ng
of total RNA, Life Technologies Ltd., Eggenstein, Germany)
were added to the reverse transcription reaction to a total
volume of 25 ml and incubated at 42°C for 60 min, followed by
denaturation at 95°C for 5 min.
PCR amplification. Duplicate samples of PCR were per-
formed in a total volume of 50 ml, respectively, each containing
10 ml of reverse transcription reaction, 35 ml of a PCR master
mix (16 mmol/liter Tris-HCl pH 8.3, 40 mmol/liter KCl,
0.4 mmol/liter MgCl2, 20 pmol of sense and antisense primer)
and 2.5 U of TAQ-DNA polymerase (Pharmacia Biosystems,
Ltd.). The mixture was overlaid with mineral oil (Sigma Ltd.,
Deisenhofen, Germany) and then subjected to 36 cycles of
PCR amplification using a DNA thermal cycler (Perkin Elmer
Ltd., Ueberlingen, Germany). The cycle profile included de-
naturation for 1 min at 94°C, annealing for 2 min at 62°C and
Abbreviations and Acronyms
L-arg 5 L-arginine
cNOS 5 constitutive nitric oxide synthase
IC 5 intracoronary
iNOS 5 inducible nitric oxide synthase
LV 5 left ventricular
LV dP/dt 5 rate of change of LV pressure
LV dP/dt max 5 maximal rate of rise of LV pressure
NO 5 nitric oxide
PCR 5 polymerase chain reaction
SP 5 substance P
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extension for 3 min at 72°C. The specificity of the amplified
PCR products was confirmed by restriction enzyme analysis
and by hybridization with specific internal oligonucleotide
probes. The amplification products of 10 ml of each PCR
reaction were separated by electrophoresis on a 1.5% agarose
gel, stained with ethidium bromide, visualized by ultraviolet
irradiation and photographed (Polaroid 665 negative film,
Polaroid Ltd., Offenbach, Germany). As a negative control, no
amplification product occurred if reverse transcriptase or total
RNA was omitted in the first-strand cDNA reaction or when
water was used as control.
Selection and synthesis of the PCR primers. Appropriate
sense and antisense primer oligonucleotides were selected
from the human cDNA sequences of iNOS (sense primer: 1614
to 1633, 59-GGGAGCATCACCCCCGTGTT-39; antisense
primer: 2012 to 2033, 59-GAGCGATTTCTTCAGTTTCTCT-
39) by computer analysis using the Oligo program (National
Biosciences Inc.). To ensure that no genomic DNA contami-
nation was present in the RNA solution, the chosen primer
oligonucleotides spanned splice junctions (18).
Data analysis. LV volumes and ejection fraction were
derived from single-plane LV angiograms by use of the area–
length method and a regression equation (19). All hemody-
namic data (Table 1) were averaged over a complete respira-
tory cycle and derived from the fast paper speed recordings.
The duration of LV electromechanical systole (Table 1), which
indicates the time to onset of LV relaxation, was measured as
the interval from the Q wave on the electrocardiogram to the
moment of maximal rate of fall of LV pressure. Data were
analyzed using repeated measures analysis of variance fol-
lowed by a multiple-comparison test (Student-Newman-
Keuls). Statistical significance was set at a two-tailed probabil-
ity level ,0.05.
Results
IC co-infusion of SP and L-arg. Figure 1 shows represen-
tative electrocardiograms of LV dP/dt, LV microtip pressure
and right atrial pressure before and during IC infusion of SP
and during IC co-infusion of SP and L-arg. In all patients,
maximal hemodynamic changes occurred during IC infusion of
SP after 2 min of infusion and during IC co-infusion of SP and
L-arg after 2 min of co-infusion. Table 1 (top) shows baseline
hemodynamic data and the changes observed during IC infu-
sion of SP and IC co-infusion of SP and L-arg. IC coinfusion of
SP and L-arg resulted at the time of maximal effect in a fall in
LV peak systolic pressure, which was significantly larger (p ,
0.01) than the maximal fall observed during IC infusion of SP
(Fig. 2). IC co-infusion of SP and L-arg induced similar changes
in LV end-systolic pressure and in LV end-diastolic pressure.
Figure 1. Representative electrocardiograms (three leads) of LV
dP/dt, LV pressure (LVP) and right atrial pressure (RAP) during
control conditions; after 2 (29IC-SP) and 5 min (59IC-SP) of IC
infusion of SP, respectively; after 2 (29IC-SP1L-arg) and 8 min
(89IC-SP1L-arg) of IC co-infusion of SP and L-arginine, respectively;
and 5 min after cessation of co-infusion (59Post-IC).
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Partial recovery of LV pressures was observed at the end of the
IC infusion of SP and at the end of the IC co-infusion of SP
and L-arg. Recovery was almost complete by 5 min after
cessation of the IC co-infusion.
IC infusion of L-arg. Table 1 (bottom) shows baseline
hemodynamic data and the changes observed during IC infu-
sion of L-arg. Baseline recordings were obtained in control
conditions (n 5 3) or during intravenous infusion of dobut-
amine (n 5 5), which raised (mean 6 SEM) heart rate from
83 6 6 to 120 6 5 beats/min (p , 0.005) and LV dP/dt max
from 1,520 6 138 to 2,820 6 132 mm Hg/s (p , 0.0005) and
lowered LV end-diastolic pressure from 13 6 1 to 8 6
1 mm Hg (p , 0.01) and duration of LV electromechanical
systole from 399 6 10 to 282 6 10 ms (p , 0.0005). Changes
during IC infusion of L-arg are shown after 2 min of infusion at
a time corresponding to the moment of maximal effect during
IC co-infusion of SP and L-arg, during IC infusion of L-arg after
8 min of infusion (i.e., just before cessation of infusion) and
5 min after cessation of IC infusion of L-arg. IC infusion of
L-arg caused no significant changes in LV pressures during or
after infusion (Fig. 2). PCR bands indicating expression of
iNOS mRNA were present in five of the six patients in whom
Table 1. Myocardial Contractile Effects of Intracoronary L-Arginine
Effects of IC Co-Infusion of SP and L-arg (n 5 8)
Baseline D29IC-SP (A) D59IC-SP (B) D29IC-SP1L-arg (C) D89IC-SP1L-arg (D) D59Post-IC (E)
HR (beats/min) 82 6 4 1 6 1 3 6 2 4 6 2* 3 6 1 2 6 2
LVPSP (mm Hg) 127 6 9 27 6 2†‡ 24 6 1†§ 216 6 4†\¶ 26 6 3 21 6 2
LVESP (mm Hg) 77 6 5 22 6 1# 21 6 1§ 210 6 4†¶ 24 6 3 23 6 2
LVEDP (mm Hg) 15 6 2 21 6 1# 0 6 1§ 23 6 1†\ 0 6 1 0 6 1
LV dP/dt max (mm Hg/s) 1,277 6 90 229 6 17 3 6 27 28 6 29 217 6 21 31 6 30
LV dP/dt min (mm Hg/s) 1,504 6 131 276 6 46 26 6 27 292 6 55 240 6 32 53 6 38
LVEST (ms) 399 6 10 26 6 4 29 6 5 212 6 5 0 6 2 25 6 7
Effects of IC Infusion of L-arg (n 5 8)
Baseline D29IC-L-arg (C) D89IC-L-arg (D) D59Post-IC (E)
HR (beats/min) 107 6 8 2 6 1*¶ 4 6 2* 5 6 2*
LVPSP (mm Hg) 128 6 6 1 6 2 22 6 2 24 6 3
LVESP (mm Hg) 67 6 4 21 6 1 24 6 2 26 6 3
LVEDP (mm Hg) 10 6 1 0 6 0.5 21 6 0.5 21 6 0.5
LV dP/dt max (mm Hg/s) 2,246 6 286 24 6 34 54 6 26 64 6 36
LV dP/dt min (mm Hg/s) 1,979 6 228 39 6 66 268 6 70 2129 6 68
LVEST (ms) 329 6 27 26 6 2† 25 6 2 29 6 3†
*Minimal 95% confidence interval .0. †Maximal 95% confidence interval ,0. ‡p , 0.01, A versus C. §p , 0.05, B versus C. \p , 0.05, C versus D. ¶p , 0.05, C
versus E. #p , 0.05, A versus C. Data presented are mean value 6 SEM. L-arg 5 L-arginine; HR 5 heart rate; IC 5 intracoronary; LV dP/dt max 5 maximal rate
of rise of LV pressure; LV dP/dt min 5 maximal rate of fall of LV pressure; LVEDP 5 left ventricular end-diastolic pressure; LVESP 5 left ventricular end-systolic
pressure; LVEST 5 left ventricular electromechanical systole time; LVPSP 5 left ventricular peak systolic pressure; SP 5 substance P; D29IC-SP and D59IC-SP 5
change observed after 2 and 5 min of intracoronary infusion of substance P, respectively; D29IC-SP1L-arg and D89IC-SP1L-arg 5 change observed after 2 and 8 min
of intracoronary substance P and L-arginine co-infusion, respectively; D59Post-IC 5 change observed 5 min after cessation of intracoronary infusion; D29IC-L-arg and
D89IC-L-arg 5 change observed 2 and 8 min after intracoronary infusion of L-arginine, respectively.
Figure 2. Changes (mean 6 95% confi-
dence interval) in LV peak systolic pressure
(DLVPSP) compared with (left) baseline
during single IC infusion of SP after 2 min
of infusion at the time of maximal effect
(A), at the end of the single IC infusion of
SP (B), during IC co-infusion of SP and
L-arg after 2 min of infusion at the time of
maximal effect (C), at the end of the IC
co-infusion of SP and L-arg (D) and 5 min
after cessation of all infusions (E); and
(right) during single IC infusion of L-arg
after 2 min of infusion (C), at the end of
single IC infusion of L-arg (D) and 5 min
after cessation of infusion (E). ‡p , 0.01, A
versus C. §p , 0.05, B versus C. \p , 0.05, C
versus D.
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additional endomyocardial biopsy samples were obtained for
detection of iNOS mRNA by reverse transcription–PCR (Fig.
3).
Discussion
Myocardial contractile response to IC co-infusion of SP
and L-arg. In the present study, addition of IC L-arg potenti-
ated the LV contractile effects of coronary endothelial stimu-
lation by SP. These results resemble a previous report (4)
in transplant recipients showing attenuation by L-arg of
acetylcholine-induced vasoconstriction of epicardial coronary
conduit vessels and enhancement by L-arg of acetylcholine-
induced vasodilation of coronary resistance vessels. Both these
myocardial and vascular effects of L-arg in transplant recipients
could be attributed to increased NO production by endothelial
cells during receptor-mediated stimulation because of in-
creased provision of substrate for endothelial NO production
in the presence of L-arg (20).
Enhancement by L-arg of agonist-induced endothelium-
dependent vasodilation has also been observed in the forearm
circulation of normal control subjects (16,21), and patients
with hypercholesterolemia (22), mild coronary disease (16)
and heart failure (23) and in the coronary microcirculation of
hypercholesterolemic patients (15). This L-arg–induced en-
hancement of endothelium-dependent vasodilation is consis-
tent with NO mediation of endothelium-dependent control of
vascular tone. The present study also supports NO as a
mediator of endothelium-dependent control of myocardial
contractile performance in the human allograft, in line with
experimental findings on the paracrine myocardial contractile
effects of endothelial stimulation by SP in isolated ferret
papillary muscles (24) or in isolated ejecting guinea pig hearts
(25).
In other clinical conditions, L-arg failed to augment agonist-
induced endothelium-dependent vasodilation, which in these
situations may be mediated by other substances, such as
prostacyclin or endothelium-derived hyperpolarizing factor
(26) rather than NO. These conditions include vasomotor
responses of coronary conduit vessels in normal control sub-
jects (16) and in patients with mild coronary disease (16) and
hypercholesterolemia (15); vasomotor responses of coronary
resistance vessels in normal control subjects (16) and in
patients with mild coronary disease (16); and vasomotor
responses of forearm resistance vessels in patients with arterial
hypertension (21) and hypercholesterolemia (27). In isolated
cat papillary muscle strips, the paracrine myocardial contrac-
tile effects of endocardial stimulation by SP have also been
shown (28) not to be mediated exclusively by NO but also by
other substances such as prostaglandins.
Myocardial contractile response to IC infusion of L-arg. In
the present study, L-arg failed to influence LV contractile
performance in the absence of foregoing receptor-mediated
endothelial stimulation. Availability of L-arg therefore does
not seem to influence the baseline paracrine effects of coronary
endothelium on myocardial contractile performance. A similar
absence of effects of L-arg under baseline conditions was also
observed in conduit and resistance vessels in transplant recip-
ients (4) and hypercholesterolemic patients (15). In contrast,
intravenous L-arg causes a vasodilator response without
agonist-induced endothelial stimulation in systemic resistance
vessels of patients with heart failure (11) or with critical limb
ischemia (29) and in pulmonary resistance vessels of patients
with pulmonary hypertension (30).
In the present study, L-arg infusion provided additional
substrate not only for endothelial constitutive nitric oxide
synthase (cNOS) but also for myocardial iNOS, which was
recently shown (5) to be expressed in myocardial tissue of
transplant recipients obtained at the time of surveillance
endomyocardial biopsies. Despite myocardial expression of
iNOS mRNA in five of the six samples in the present study, a
single IC L-arg infusion failed to alter LV function. In view of
the recently reported association in transplant recipients be-
tween the myocardial expression of iNOS and LV contractile
dysfunction (5) and because of the numerous reports from
isolated cardiac preparations showing reduced contractile per-
formance after acute cytokine-induced expression of iNOS
(31–36), provision of additional substrate for myocardial iNOS
by IC L-arg infusion might have been expected to impair LV
contractile function. The failure to observe such an impair-
ment of LV function could relate to the absence of substrate
dependence of myocardial iNOS, to a relatively low myocardial
expression of iNOS in the patients studied or to unequal tissue
distribution of endothelial cNOS and myocardial iNOS. Ab-
sence of substrate dependence of iNOS seems unlikely because
in contrast to endothelial cNOS, iNOS is not regulated by
intracellular calcium and generates large amounts of NO (6,7).
Moreover, cytokine-induced NO production by iNOS in iso-
lated cardiomyocytes was recently shown (8) to be highly
dependent on L-arg transport into the cells, as evident from
cytokine-induced co-induction of cationic amino acid trans-
porters. The present investigations were performed at the time
of annual cardiac catheterization in the absence of clinical or
histologic evidence of rejection. Lewis et al. (5) also used
surveillance biopsies to establish the association between myo-
cardial expression of iNOS and LV contractile dysfunction of
the allograft. This argues in favor of a similar level of myocar-
dial expression of iNOS mRNA in the present study and in the
study by Lewis et al. A more likely cause for the unequal effects
on myocardial contractile performance of combined L-arg–SP
Figure 3. Reverse transcription–PCR amplification product of iNOS
mRNA derived from endomyocardial biopsy samples obtained from
six patients in whom a single IC L-arg infusion was performed. iNOS
mRNA was present in all biopsy samples except that from Patient 5.
bp 5 base pairs.
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infusion and single L-arg infusion seems to be the unequal
tissue distribution of endothelial cNOS and of myocardial
iNOS, which determines diffusion distance for L-arg, diffusion
distance for NO to cardiomyocytes and eventual binding of NO
to immune-related reactive oxidants.
Interactions between NO and the LV contractile response
to beta-agonists have been observed in dogs (37), in patients
with left ventricular dysfunction (38) and in transplant recipi-
ents (17). Because of the enhancement by beta-agonists of the
cardiodepressant effect of NO, we investigated, in five trans-
plant recipients, the myocardial contractile effects of IC L-arg
infusion after pretreatment with intravenous dobutamine. In
these patients, IC L-arg infusion also failed to alter LV
performance.
Study limitations. In the present study, IC L-arg was
infused at a dose of 160 mmol/min. A similar dose was used in
previous studies (15,16) and shown to potentiate endothelium-
dependent vasodilation of the coronary microcirculation in
hypercholesterolemia (15). In the present study, this dose was
also effective in potentiating the myocardial contractile effects
of SP-induced coronary endothelial stimulation. An insufficient
dosage of L-arg to influence myocardial NO production by
iNOS therefore seems unlikely. In the present study, IC L-arg
was infused for an 8-min period irrespective of the presence or
absence of co-infusion with SP. During IC co-infusion with SP,
maximal effects were observed after 2 min, or one fourth of the
total infusion time. During single IC infusion of L-arg, no effect
was observed during the entire 8-min infusion period. Because
of the longer diffusion distance from the coronary lumen to the
myocardium than to the endothelium, slower uptake of L-arg
by myocardium than by endothelium could explain failure to
observe myocardial contractile effects of single IC L-arg infu-
sion despite myocardial iNOS gene expression. A longer IC
infusion period could have revealed a direct iNOS-mediated
myocardial effect of L-arg. However, spillover into the right
atrium and concomitant vasodilator action of L-arg precludes
the use of a long IC infusion period because of inability to
distinguish a fall in LV pressure related to systemic vasodila-
tion from a fall related to iNOS-induced myocardial contractile
depression.
The fall in LV peak systolic, end-systolic and end-diastolic
pressures observed in the present study during IC infusion of
SP results from altered myocardial contractile performance
and not from peripheral vasodilation because of previous
studies in which LV contractile performance during IC infu-
sion of SP was assessed from simultaneous LV pressures and
angiograms (2,17). In these studies, IC infusion of SP induced
a similar fall in LV pressures without change in LV dP/dt max,
which was accompanied by a rise in LV end-diastolic volume
and no change in LV end-systolic volume. Unaltered LV dP/dt
max at larger LV end-diastolic volume and lower LV end-
systolic pressure at unaltered LV end-systolic volume were
consistent with reduced myocardial contractile performance
(39,40). Moreover, both the larger LV end-diastolic volume
and the failure of a right atrial infusion to reproduce the
hemodynamic changes of the IC infusion argue against vaso-
dilator effects.
The present study was limited to a group of transplant
recipients, and extrapolation of the present data to normal
control subjects warrants caution because of studies that
showed enhancement by L-arg of agonist-induced endothelium
dependent vasodilation in transplant recipients (4) but not in
normal control subjects (16). In contrast, our previous study
(2) on the LV myocardial contractile response to IC SP
reported similar hemodynamic changes in normal control
subjects and transplant recipients, although the numbers stud-
ied were too small to exclude minor differences with certainty.
The presence of iNOS in the myocardium of our study
group was derived from demonstration of iNOS mRNA by
reverse transcription PCR and not by direct demonstration of
iNOS protein. Because of posttranscriptional control of iNOS
protein translation, definite proof of myocardial presence of
iNOS requires direct demonstration of myocardial iNOS pro-
tein, which was not performed in the present study.
Conclusions. IC L-arg potentiates the paracrine myocardial
contractile effects of receptor-mediated coronary endothelial
stimulation, probably by providing more substrate for coronary
endothelial cNOS. Despite myocardial expression of iNOS
gene, a similar single IC infusion of L-arg failed to induce LV
contractile effects.
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